Literature DB >> 2005905

Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).

J K Batra1, D J Fitzgerald, V K Chaudhary, I Pastan.   

Abstract

Two single-chain immunotoxins directed at the human transferrin receptor have been constructed by using polymerase chain reaction-based methods. Anti-TFR(Fv)-PE40 is encoded by a gene fusion between the DNA sequence encoding the antigen-binding portion (Fv) of a monoclonal antibody directed at the human transferrin receptor and that encoding a 40,000-molecular-weight fragment of Pseudomonas exotoxin (PE40). The other fusion protein, DT388-anti-TFR(Fv), is encoded by a gene fusion between the DNA encoding a truncated form of diphtheria toxin and that encoding the antigen-binding portion of antibody to human transferrin receptor. These gene fusions were expressed in Escherichia coli, and fusion proteins were purified by conventional chromatography techniques to near homogeneity. In anti-TFR(Fv)-PE40, the antigen-binding portion is placed at the amino terminus of the toxin, while in DT388-anti-TFR(Fv), it is at the carboxyl end of the toxin. Both these single-chain immunotoxins kill cells bearing the human transferrin receptors. However, anti-TFR(Fv)-PE40 was usually more active than DT388-anti-TFR(Fv), and in some cases it was several-hundred-fold more active. Anti-TFR(Fv)-PE40 was also more active on cell lines than a conjugate made by chemically coupling the native antibody to PE40, and in some cases it was more than 100-fold more active.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005905      PMCID: PMC359914          DOI: 10.1128/mcb.11.4.2200-2205.1991

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   5.069


  24 in total

1.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr approximately 6000 region of the toxin.

Authors:  J M Rolf; H M Gaudin; L Eidels
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

Review 3.  Genetic engineering of immunotoxins.

Authors:  R J Youle; L Greenfield; V G Johnson
Journal:  Cancer Treat Res       Date:  1988

Review 4.  Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development.

Authors:  J R Murphy
Journal:  Cancer Treat Res       Date:  1988

5.  Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity.

Authors:  V K Chaudhary; Y Jinno; D FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 12.779

6.  A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin.

Authors:  V K Chaudhary; C Queen; R P Junghans; T A Waldmann; D J FitzGerald; I Pastan
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

7.  Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.

Authors:  J K Batra; D FitzGerald; M Gately; V K Chaudhary; I Pastan
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.486

8.  Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.

Authors:  M Ogata; V K Chaudhary; I Pastan; D J FitzGerald
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.486

9.  Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.

Authors:  T Kondo; D FitzGerald; V K Chaudhary; S Adhya; I Pastan
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.486

10.  Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.

Authors:  J K Batra; Y Jinno; V K Chaudhary; T Kondo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 12.779

View more
  17 in total

1.  Infectious enveloped RNA virus antigenic chimeras.

Authors:  S D London; A L Schmaljohn; J M Dalrymple; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  Recombinant antibody-metallothionein: design and evaluation for radioimmunoimaging.

Authors:  C Das; P V Kulkarni; A Constantinescu; P Antich; F R Blattner; P W Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 3.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

4.  Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action.

Authors:  D Rathore; J K Batra
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

5.  Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.

Authors:  Abid R Mattoo; David J FitzGerald
Journal:  Int J Cancer       Date:  2012-08-16       Impact factor: 7.396

6.  Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.

Authors:  M Varughese; A V Teixeira; S Liu; S H Leppla
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Authors:  Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J Fitzgerald
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

8.  Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.

Authors:  Kathleen F Pirollo; Antonina Rait; Qi Zhou; Xin-qiao Zhang; Jain Zhou; Chang-Soo Kim; William F Benedict; Esther H Chang
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

Review 9.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

10.  Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.

Authors:  Robert Sarnovsky; Tara Tendler; Matheusz Makowski; Maureen Kiley; Antonella Antignani; Roberta Traini; Jingli Zhang; Raffit Hassan; David J FitzGerald
Journal:  Cancer Immunol Immunother       Date:  2009-11-29       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.